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Summary
Background: Fabry disease is an X-linked lysosomal storage disorder caused by mutations of the
-galactosidase A (GLA) gene, and the disease is a relatively prevalent cause of left ventriculardisease;
Fabry disease;
GLA mutations;
MLPA;
Mutation analysis
hypertrophy followed by conduction abnormalities and arrhythmias. Mutation analysis of the
GLA gene is a valuable tool for accurate diagnosis of affected families. In this study, we carried
out molecular studies of 10 unrelated families diagnosed with Fabry disease.
Materials and methods: Genetic analysis of the GLA gene using conventional genomic sequenc-
ing was performed in 9 hemizygous males and 6 heterozygous females. In patients with no
mutations in coding DNA sequence, multiplex ligation-dependent probe ampliﬁcation (MLPA)
and/or cDNA sequencing were performed.
∗ Corresponding author. Tel.: +81 99 275 5318; fax: +81 99 265 8447.
E-mail address: takenaka@m.kufm.kagoshima-u.ac.jp (T. Takenaka).
0914-5087/$ — see front matter © 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Results: We identiﬁed a novel exon 2 deletion (IVS1 IVS2) in a heterozygous female by MLPA,
which was undetectable by conventional sequencing methods. In addition, the g.9331G>A muta-
tion that has previously been found only in patients with cardiac Fabry disease was found in 3
unrelated, newly-diagnosed, cardiac Fabry patients by sequencing GLA genomic DNA and cDNA.
Two other novel mutations, g.8319A>G and 832delA were also found in addition to 4 previously
reported mutations (R112C, C142Y, M296I, and G373D) in 6 other families.
Conclusions: We could identify GLA gene mutations in all hemizygotes and heterozygotes from 10
families with Fabry disease. Mutations in 4 out of 10 families could not be identiﬁed by classical
genomic analysis, which focuses on exons and the ﬂanking region. Instead, these data suggest
that MLPA analysis and cDNA seque
ardi
I
F
a
(
s
t
[
s
d
C
p
a
e
m
t
[
a
e
t
p
d
o
o
d
n
i
l
b
a
w
r
F
m
o
t
G
a
q
m
f
i
c
t
t
s
ﬂ
m
i
S
a
l
p
a
c
d
s
m
e
b
t
s
p
h
o
s
F
m
m
M
P
W
u
t
p
1
G
GLA activity was measured on plasma and ﬁbroblast lysates
from Fabry patient samples by a ﬂuorometric assay as
described [16]. Samples were added to a microtiter-platewith Fabry disease.
© 2011 Japanese College of C
ntroduction
abry disease is an X-linked inherited disorder caused by
deﬁciency of a lysosomal hydrolase, -galactosidase A
GLA; EC 3.2.1.22) [1]. This enzymatic defect leads to the
ystemic accumulation of glycosphingolipids, mainly globo-
riaosylceramide (Gb3), and results in multiple organ failure
2]. In male patients with Fabry disease, acroparesthe-
ias, angiokeratoma, hypohidrosis, corneal opacities, and
ysfunction of the kidney, brain, and heart are observed.
ardiac involvement, including left ventricular hypertro-
hy, conduction abnormalities, arrhythmias, and valvular
bnormalities, contributes to substantial morbidity and
arly death due to heart failure or ventricular arrhyth-
ias. The incidence of Fabry disease has been estimated
o be approximately 1 in 40,000 to 1 in 117,000 male births
2,3].
Our laboratory has demonstrated that the cardiac vari-
nt of Fabry disease with manifestations limited to the heart
xists in 3—4% of male patients with left ventricular hyper-
rophy of unknown etiology in the Japanese and British
opulation [4,5]. We also reported a renal variant of Fabry
isease among hemodialysis patients with unknown etiol-
gy [6]. In addition, recent studies have shown that 1.2%
f young patients with unexplained acute cerebrovascular
isease have Fabry disease [7]. Moreover, a large cohort of
ewborn screening revealed high incidence of the disease (1
n 1250 to 1 in 3100 male newborns) [8,9], thus the preva-
ence of Fabry disease may be much higher than previously
elieved. Currently enzyme replacement therapy is avail-
ble, however, the therapeutic efﬁcacy is limited in patients
ith late stage of the disease [10—13]. Thus, early and accu-
ate diagnoses are of great importance for the treatment of
abry disease.
Diagnosis of Fabry disease can be readily made in
ale patients by an enzymatic GLA assay using plasma
r white blood cells. However, this analysis often fails
o distinguish Fabry heterozygotes with high residual
LA activity from normal individuals. Therefore, mutation
nalysis is a valuable tool for diagnosis and subse-
uent genetic counseling of affected families. About 500
utations in the GLA gene have been described so
ar (http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GLA),
ncluding missense and nonsense mutations as well as
hanges affecting splice sites. It has been difﬁcult, however,
o detect single allele deletions in heterozygotes or alterna-
ive splicing due to mid-intronic mutations by conventional
r
b
d
dnce should be considered in genetic testing surveys of patients
ology. Published by Elsevier Ltd. All rights reserved.
equencing methods, which primarily cover exons and their
anking intronic regions.
Mutations that cause cardiac Fabry disease include
issense mutations, a small in-frame deletion and a mid-
ntronic genetic lesion g.9331G>A of the GLA gene [2,14].
o far, the g.9331G>A mutation is a mutation reported only
mong cardiac variants of Fabry disease. Thus, further col-
ections of mutation data from diagnosed cardiac Fabry
atients could provide insights concerning the pathogenesis
nd mechanism of organ-speciﬁc damage in this context.
Recently, a multiplex ligation-dependent probe ampliﬁ-
ation (MLPA) method has been introduced to detect large
eletions in Fabry disease [15]. MLPA is based on the
imultaneous hybridization of several probes followed by a
ultiplex polymerase chain reaction (PCR) ampliﬁcation of
ach exon, so that relative copy number of each exon can
e estimated.
The aim of this report is to demonstrate that GLA muta-
ional screening is improved by adding MLPA and cDNA
equencing to the mutation hunting repertoire. For this pur-
ose, one classic and three cardiac Fabry patients, who
ad failed to show any point mutations after sequencing
f coding DNA were analyzed by MLPA and reverse tran-
criptional PCR (RT-PCR) methods with cDNA sequencing.
urthermore, we also present 2 novel Fabry disease-causing
utations in addition to conﬁrming 4 previously reported
utations.
aterials and methods
atients
e performed GLA gene analyses on 15 patients from 10
nrelated families (9 males and 6 females, Table 1). All par-
icipants completed a consent form for diagnostic testing
rior to genetic analyses. The clinical characteristics of the
5 patients from 10 families are summarized in Table 1.
LA activity assayseader (Twinkle LB970, Berthold Technology, Bad Wild-
ad, Germany), and the 4-methylumbelliferone product was
etermined quantitatively by comparison with known stan-
ards (Sigma—Aldrich, St. Louis, MO, USA). The protein
MLPA assay and cDNA sequencing of GLA gene
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oncentration of cell lysates was determined by the BCA
rotein Assay Kit (Pierce, Rockford, IL, USA). GLA activity in
ach sample was measured in triplicate.
solation of genomic DNA, ampliﬁcation, and
onventional sequencing analysis
enomic DNA was extracted from peripheral blood mononu-
lear cells by standard procedure [17]. For conventional
enetic examination, the GLA gene (exons 1—7 and their
anking region) was ampliﬁed in 4 fragments correspond-
ng to exons 1, 2, 3—4, and 5—7, using primers in Table 2.
CR reactions were carried out in a total volume of 50l
ontaining 1× PCR buffer for KOD-Plus (Toyobo, Tokyo,
apan), 0.8mM MgSO4, 0.2mM dNTP, 0.3M of each primer,
U KOD-Plus-DNA polymerase (Toyobo), and 100 ng genomic
NA. Reaction conditions were as follows: For exons 1
nd 2: 95 ◦C for 6.5min, followed by 35 cycles of 30 s
t 94 ◦C, 45 s at 61 ◦C for exon 1 or 58 ◦C for exon 2,
5 s at 72 ◦C, and a ﬁnal extension at 72 ◦C for 7min.
or exons 3—4 and 5—7: 95 ◦C for 6.5min, followed by
5 cycles of 30 s at 94 ◦C, 45 s at 57 ◦C, 45 s at 72 ◦C,
nd a ﬁnal extension at 72 ◦C for 7min. Sequencing reac-
ions were performed with BigDye Terminator v3.1 Cycle
equencing Kit (Applied Biosystems, Foster City, CA, USA)
s per the manufacturer’s instructions. Sequencing was per-
ormed on an ABI PRISM 3100 Genetic Analyzer (Applied
iosystems). Forward or reverse sequences were analyzed
sing sequencing primers in Table 2 and compared with
he genomic GLA reference sequence (GenBank Accession
o. X14448).
ultiplex ligation-dependent probe ampliﬁcation
ssay
he MLPA protocol followed the manufacturer’s instructions
MRC Holland, Amsterdam, The Netherlands) using the SALSA
LPA P159 GLA probemix (Lot # 0107). This contains, in addi-
ion to eight GLA probes located in 7 different GLA exons
one probe for each exon and two probes for exon 2), 4
robes outside the GLA genomic locus in 3 ﬂanking genes
PLP1 probe, 2.4 Mb upstream of GLA gene; HNRPH2 probe,
00 bp upstream of GLA gene; RPL36A probe, 2 kb down-
tream of GLA gene). The PCR products were analyzed on the
BI Prism 3100 Genetic Analyzer with GeneMapper Software
ersion 4.0. GeneScan 600 LIZ Size Standard (Applied Biosys-
ems) was used as an internal standard. Data obtained were
nalyzed by Peak Scanner Software v1.0 (Applied Biosys-
ems).
The PCR to detect the exact breakpoints of mono-allelic
eletion of GLA gene in patients 2-1 was performed using
he following primers: IVS 1 (5′-TGAGGGTTGAGGCTGGATTA-
′); IVS 2 (5′-AGCTCTGGCACATGGAGAAT-3′). The ﬁrst step
f reaction mixture contained: 12l of 3.3× XL buffer II,
.5M of primers, 2mM of dNTP, 2.5mM Mg (OAc)2 (Perkin
lmer, Foster City, CA, USA) in a total volume of 40l.
he ﬁrst thermocycler condition was as follows: 80 ◦C for
min; 25 ◦C for 2min with an AmpliWax PCR Gem 50 (Takara,
yoto, Japan). The second step of the reaction mixture
as performed on the ﬁrst mixture (total volume of 60l)
ontaining: 18l of 3.3× XL buffer II, 2l of rTth DNA
348
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Table 2 Primer sequences for ampliﬁcation and sequencing of the GLA gene.
Fragment Nucleotide positiona Sequence Size (bp)
Genomic DNA ampliﬁcation
Exon 1 926—943 Forward: 5′-GGATCACTAAGGTGCCGC-3′ 579
1504—1485 Reverse: 5′-AAAAGCAGCAGCAGAGTCGG-3′
Exon 2 4968—4987 Forward: 5′-CTTGTGATTACTACCACACT-3′ 367
5334—5312 Reverse: 5′-AACAAGCTTCTGTACAGAAGTGC-3′
Exons 3—4 7071—7094 Forward: 5′-TAGCTCAGCAGAACTGGGGGATTT-3′ 1440
8510—8494 Reverse: 5′-GTAAGTAACGTTGGACT-3′
Exons 5—7 10,078—10,094 Forward: 5′-CTCACAAGGATGTTAGT-3′ 1224
11,301—11,285 Reverse: 5′-CAGGAAGTAGTAGTTGG-3′
Sequencing primers
Exon 1 reverse 1460—1441 5′-AACTGTTCCCGTTGAGACTC-3′
Exon 2 reverse 5334—5312 5′-AACAAGCTTCTGTACAGAAGTGC-3′
Exon 3 forward 7198—7218 5′-TGGTTCTCTCTTTCTGCTACC-3′
Exon 4 forward 8261—8280 5′-TATAGCCCCAGCTGGAAATT-3′
Exon 5 reverse 10,349—10,365 5′-TATTTACCTTGAATGTC-3′
Exon 6 reverse 10,776—10,760 5′-AGATTTAGGCCCAAGAC-3′
Exon 7 reverse 11,301—11,285 5′-CAGGAAGTAGTAGTTGG-3′
a Positions of primers are numbered according to GenBank database entry X14448 (gene).
Table 3 Sequence variations and their localization in the exons and introns of the GLA gene.
Family No. Nucleotide change Exon Intron Amino acid change Mutation type Number of References
cDNA gDNA Males Females
1 c. 335C>T g.5233C>T 2 p. R112C Missense 0 1 [24]
2 2 1—2 Large deletion 0 1 This report
3 c. 425G>A g.7324G>A 3 p. C142Y Missense 1 1 [25]
4 None g.8319A>G 3 Exon 4 skipping Splicing mutation 1 1 This report
5 None g.9331G>A 4 Alternative splicing Splicing variant 1 0 [14]
6 None g.9331G>A 4 Alternative splicing Splicing variant 1 0 [14]
7 None g.9331G>A 4 Alternative splicing Splicing variant 1 0 [14]
8 c. 832delA g.10540delA 6 p. V281stop Deletion 2 1 This report
9 c. 888G>A g.10596G>A 6 p. M296I Missense 1 1 [4]
10 c. 1118G>A g.11096G>A 7 p. G373D Missense 1 0 [26]
Mutations are described according to the GLA cDNA (GenBank: GCOXM 100539) or gDNA (NCBI: X14448) sequence. GLA, -galactosidase A.
t
t
a
c
A
p
f
a
a
p
s
ﬁ
d
(
t
(
ﬂ
i
i
A
G
o
t
i
1
ﬁ
o
p
g
i
a
t
p
t
t
i
t
d
p
1
h
(
i
d
e
3
f
t
t
d
(
m
G
P
iMLPA assay and cDNA sequencing of GLA gene
Polymerase XL, 1g of genomic DNA. The second thermo-
cycler condition was as follows: 95 ◦C for 2min; 30 cycles
at 94 ◦C for 15 s, 55 ◦C for 7min and a ﬁnal extension at
72 ◦C for 10min. Following ampliﬁcation, the PCR product
was subcloned using the TA cloning kit (Invitrogen, Carls-
bad, CA, USA) and sequenced using a sequencing primer
(5′-AAGTTTCATGTGACCCTGTGG-3′).
RNA isolation, cDNA synthesis, and quantitative
real-time PCR for GLA
Total RNA was extracted from Fabry patient peripheral
blood mononuclear cells or Fabry patient ﬁbroblasts using
RNAqueous (Applied Biosystems) as per the manufacturer’s
instructions. Normal human skin ﬁbroblasts (NHSF46) were
obtained from Riken Cell Bank (Tsukuba, Ibaraki, Japan)
as a normal control. We performed reverse transcriptional
reaction using High Capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems) as per the manufacturer’s
instructions.
To determine the sequence of the cDNA region of
GLA that included exons 2—6, we performed the ﬁrst
PCR and nested PCR reactions with speciﬁc primers as
described previously [18]. The PCR product was sub-
cloned using the TA cloning kit (pCR2.1) and sequenced
in both directions (5′-TGTAAAACGACGGCCAGT-3′, 5′-
CACAGGAAACAGCTATGAC-3′).
Quantitative real-time PCR for GLA mRNA expression was
performed with Taqman Universal PCR Master Mix (Applied
Biosystems) with Taqman Gene Expression Assays (Applied
Biosystems). Each gene of Taqman Gene Expression Assays
mixture is as follows: -gal A (Assay ID: Hs00609238 m1) and
GAPDH (Hs99999905 m1). The PCR condition was as follows:
50 ◦C for 2min, 95 ◦C for 10min, 40 cycles of 95 ◦C for 15 s
and 60 ◦C for 1min. Signals were detected with an ABI7300
Real-Time PCR System (Applied Biosystems).
Results and discussion
Sequence variations found in GLA gene from all patients are
summarized in Table 3. In 10 newly identiﬁed families, 8
different mutations were identiﬁed including 3 novel muta-
tions.
We report here for the ﬁrst time a novel mutation that
is a large fragment deletion IVS1 IVS2 of exon 2 detected
in Fabry patient 2-1. Notably, we detected this mutation
in a heterozygous female with the disorder. This 23-year-
old female patient with anhydrosis, acroparesthesia, and
angiokeratoma along with low plasma GLA activity was
clinically diagnosed as having Fabry disease; however, con-
ventional direct DNA sequencing of all exons and their
ﬂanking regions did not reveal any mutation. Quantitative
real-time PCR designed to amplify the GLA mRNA exons
2—3 boundary revealed 50% decreases in levels of GLA tran-
scripts as compared to normal human ﬁbroblasts (Fig. 1A). In
addition, intracellular GLA activity from the patient-derived
ﬁbroblasts was reduced to 50% of normal as well (Fig. 1B).
These results prompted us to suspect an allelic deletion
of exon 2 and/or exon 3. Thus, we employed the recently
developed MLPA method [15] to detect large fragment dele-
tions. MLPA revealed a novel large deletion spanning across
4
p
s
n
r349
he exon 2 of GLA gene (Fig. 1C). When compared to con-
rols, gene electropherograms of the patient sample showed
reduction in relative ﬂuorescence intensity of both spe-
iﬁc MLPA probes located on exon 2 of GLA gene (Fig. 1C).
fter quantiﬁcation, obtained by calculating the relative
eak area ratio, the reduction of the relative copy numbers
or GLA exon 2 was estimated to be 38—49%. These values
re consistent with the presence of a normal and abnormal
llele of the GLA gene.
Subsequently we determined the breakpoint site in this
atient’s sequence by PCR ampliﬁcation and subsequent
equencing analysis (Fig. 1D and E). This deletion was con-
rmed using 2 primer pairs (IVS1 and IVS2) and revealed a
eletion of 3444 base pairs with the start point at g.2934
intron 1) and the endpoint at g.6378 (intron 2). Notably,
he breakpoint region contained an identical 11-bp sequence
Fig. 1E, underlined). The large deletion was found to be
anked with 5′ breakpoint within the ﬁrst Alu repeat in
ntron 1 and 3′ breakpoint within the seventh Alu repeat
n intron 2 of the GLA gene, which might result from Alu-
lu repeat recombination (Fig. 1F). Among more than 500
LA gene mutations detected in patients with Fabry disease,
nly 2 deletions resulting from possible Alu-Alu recombina-
ions have been reported [19,20]. The gene rearrangement
n this Fabry patient could be facilitated by the identical
1-oligonucleotides in the breakpoint region. This is the
rst reported heterozygote case carrying a large deletion
f GLA gene determined by MLPA assay with precise break-
oint sequence. Since heterozygous allelic deletion of GLA
ene cannot be detected by conventional direct sequenc-
ng, unless laborious and time-consuming Southern blotting
nalysis is utilized, MLPA assay can be a valuable tool for
he diagnosis of Fabry disease. It should be noted that MLPA
robes are not sensitive enough to detect small deletions if
he sequence is located outside the probe’s target site.
Ishii et al. [14] have identiﬁed g.9331G>A intronic muta-
ion, which demonstrates a rare alternative splicing that
ntroduce a 57-nucleotide intronic sequence into the GLA
ranscript only in 6 unrelated cardiac variants of Fabry
isease. We report here 3 more unrelated cardiac Fabry
atients with the g.9331G>A mutation (Table 1, Patients 5-
, 6-1, and 7-1). These 3 patients were admitted to our
ospital to further examine left ventricular hypertrophy
Fig. 2A—C) with decreased levels of plasma GLA activ-
ty. These patients lack major phenotype of classical Fabry
isease, for example, anhydrosis, acroparesthesia, angiok-
ratoma, renal dysfunction, or stroke (Table 1). Two of the
patients (Patients 5-1, 6-1, Table 1) had congestive heart
ailure and these 2 patients showed localized thinning of
he left ventricular posterior wall which is a characteris-
ic ﬁnding in patients with advanced stage cardiac Fabry
isease [21]. These 3 patients had high urine Gb3 levels
data not shown); however, we were unable to identify any
utation in the exonic or ﬂanking intronic regions of the
LA gene. Therefore, we checked GLA transcripts by RT-
CR. Direct sequencing of the RT-PCR products revealed an
nsertion of 57-nucleotides intronic sequence between exon
and exon 5 with g.9331 G>A transition (Fig. 2D), as has
reviously been reported by Ishii et al. [14]. Note that the
ame alternative splicing that introduce the identical 57-
ucleotide intronic sequence into the GLA transcript was
eported (g.9273C>T intronic mutation) in a classical Fabry
350 M. Yoshimitsu et al.
Figure 1 (A) Quantitative real-time polymerase chain reaction (PCR) for -galactosidase A (GLA) mRNA expression in skin ﬁbrob-
lasts from a normal control and a Fabry heterozygote (Patient 2-1, Table 1). (B) Intracellular GLA enzyme activity in skin ﬁbroblasts
from a normal and a Fabry heterozygote (Patient 2-1, Table 1). (C) Detection of GLA exon alterations by multiplex ligation-dependent
probe ampliﬁcation (x-axis: fragment size, y-axis: ﬂuorescence intensity). Blue peaks indicate 24 probes (P159 GLA probemix, lot
# 0107) including 8 probes recognizing the GLA exons (indicated by arrows in lane 1). Orange peaks indicate size standard controls
(GeneScan 600 LIZ Size Standard). Both asterisks indicate decreased peak heights corresponding to deleted exon 2. (D) PCR ampliﬁ-
c s 1 an
a ns o
n uenc
h
d
cation of genomic DNA from normal and deleted allele of intron
cross the deletion joint in the deleted exon 2 allele. The regio
ormal intron 1 and normal intron 2 with the consensus Alu seqemizygous patient [22], thus the amino acid substitution
ue to the 57-nucleotide insertion itself may not be the
ause of the cardiac phenotype. Further examination of the
n
o
sd 2 (normal control and Patient 2-1). (E) Nucleotide sequences
f breakpoint are underlined. (F) Alignment of Alu sequences of
e. The regions of breakpoint are underlined.ormal/alternative splicing ratio of GLA transcripts in each
rgan needs to be carefully characterized. Recent rather
urprising reports from a large newborn screening identi-
MLPA assay and cDNA sequencing of GLA gene 351
Figure 2 Echocardiogram obtained from Patients 5-1 (A), 6-1 (B), and 7-1 (C). Parasternal long-axis view (a, c, e) and short-axis
view (b, d, f) showed left ventricular hypertrophy with an interventricular septal wall thickness of 13—17mm and a left ventricular
posterior wall thickness of 13—14mm. In 2 patients who had congestive heart failure (Patients 5-1 and 6-1), localized thinning of
the basal posterior wall of the left ventricle was observed (indicated by arrows). The wall thickness of the thinned left ventricular
posterior wall was 4mm in Patient 5-1 and 7mm in Patient 6-1, respectively. (D) Sequence of -galactosidase A cDNA from Patient
5-1. Insertion of 57-nucleotide intronic sequence between exon 4 and exon 5 is enclosed in the box. The G to A transition at g.9331
is indicated by an arrow.
352 M. Yoshimitsu et al.
Figure 3 (A) Partial genomic DNA sequence of -galactosidase A (GLA) intron 3 and exon 4, indicating the single-base substitution
of A to G at g.8319 in hemizygous Patient 4-1 and heterozygous Patient 4-2. The sequence from a normal control is shown in the
upper panel, and that from hemizygous Patient 4-1 (lower panel, left) and heterozygous Patient 4-2 (lower panel, right). (B) Partial
cDNA sequence of GLA, indicating exon 4 skipping between exon 3 and exon 5 in hemizygous Patient 4-1 (C) Partial genomic DNA
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1equence of GLA exon 6, indicating the single-base deletion o
atient 8-3.
ed a high frequency of Taiwanese males with Fabry disease
1 in 1250), and 82% having the g.9331G>A mutation [9].
n addition, 33% of the maternal grandfathers of this cohort
aving the mutation developed left ventricular hypertrophy.
urther accumulation of genetic and clinical information of
his g.9331G>A mutation will determine its natural history,
rgan speciﬁc pathogenesis, and optimal timing of enzyme
eplacement therapy. Monserrat et al. reported that 15 out
f 508 patients (3%) with hypertrophic cardiomyopathy had
ow GLA activity, however GLA mutations in coding sequence
ere not identiﬁed in 4 of the 15 patients, which subse-
uently excluded them from a diagnosis of Fabry disease
23]. Our approach using cDNA sequencing and the MLPA
ssay in addition to conventional direct genomic sequencing
ay increase the accuracy of the diagnosis. This may facil-
tate identiﬁcation of non-symptomatic carriers, who need
areful follow-up and may be good candidates for enzyme
eplacement therapy with the possibility of improved efﬁ-
acy due to early intervention.
The other 2 novel mutations detected in this study
nclude g.8319A>G and c.832delA. The g.8319A>G muta-
c
i
G
a
et g.10540 (c.832) in hemizygous Patient 8-1 and heterozygous
ion detected in Family 4 (Fig. 3A) altered processing of
he GLA transcript. An ag-to-gg transversion at 3′ splic-
ng acceptor sites of intron 4 was found in a classically
ffected family (Patients 4-1, 4-2, Table 1). The mutation
esulted in whole exon 4 skipping that lead to prema-
ure chain termination (Fig. 3B). In Family 8, a c.832delA
utation (Fig. 3C) was detected. This was a classically
ffected family as well (Patients 8-1, 8-2, and 8-3, Table 1);
his deletion caused a frameshift from codon 278 to a
remature termination codon at position 281. In the remain-
ng 4 families, 4 previously reported missense mutations
R112C, C142Y, M296I, and G373D) were identiﬁed (Table 3)
4,14,24—26].
In conclusion, we could identify all disease-causing
utations in 9 hemizygotes and 6 heterozygotes from
0 unrelated families with Fabry disease by utilizing
onventional direct genomic sequencing, cDNA sequenc-
ng, and the MLPA assay. In Fabry patients with normal
LA genomic and/or ﬂanking sequence, MLPA assay
nd/or complete cDNA sequencing should be consid-
red.
[[
[
[
[
[
[
[
[
[
[
[
[MLPA assay and cDNA sequencing of GLA gene
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